Research programme: non alpha beta T-cell receptor immunotherapy - Juno Therapeutics
Alternative Names: Gamma delta T cell receptor immunotherapy - Juno TherapeuticsLatest Information Update: 28 Dec 2023
At a glance
- Originator Juno Therapeutics
- Developer Editas Medicine; Juno Therapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in USA
- 26 Nov 2019 Editas Medicine and Juno Therapeutics expand the agreement to co-develop non-alpha beta T cell receptor (TCR) therapies in USA for Cancer
- 12 Nov 2019 Early research in Cancer in USA (unspecified route)